Diabetic retinopathy (DR), the most common microvascular complication of diabetes mellitus, represents the leading cause of acquired blindness in the working-age population. Due to the potential absence of symptoms in the early stages of the disease, the identification of clinical biomarkers can have a crucial role in the early diagnosis of DR as well as for the detection of prognostic factors. In particular, imaging techniques are fundamental tools for screening, diagnosis, classification, monitoring, treatment planning and prognostic assessment in DR. In this context, the identification of ocular and systemic biomarkers is crucial to facilitate the risk stratification of diabetic patients; moreover, reliable biomarkers could provide prognostic information on disease progression as well as assist in predicting a patient’s response to therapy. In this context, this review aimed to provide an updated and comprehensive overview of the soluble and anatomical biomarkers associated with DR.
Monocentric retrospective case series to describe clinical and molecular peculiarities in a series of pediatric patients in attempting a possible genotype-phenotype correlation. We included 13 pediatric patients from 7 unrelated families (ages 1-18) with biallelic pathogenic and likely pathogenic variants in RDH12 gene. For all our patients segregation analyses were performed in their parents and affected siblings. According to their cooperation, patients underwent a complete ophtalmic examination and imaging with full field standard electroretinography (ffERG), spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF). According to previous studies, we did not observe a conclusive genotype-phenotype correlation in our series, nevertheless we reported 2 new RDH12 likely pathogenic variants. Also, we report clinical data on pediatric patients, with the fundus imaging in the youngest child (2 yo) described in the literature in whom retinal dystrophic changes are already present. This study includes a collection of genotypic and phenotypic data from children with RDH12-associated IRD. These findings will help further characterize RDH12-related retinopathy. Determining the time window of onset of dystrophic changes is critical to research the correct timing for administering possible therapies. More extensive and functional studies are needed in view of the opportunity of gene replacement therapy for RDH12 associated IRD.